|
|
|
VGX Pharmaceuticals
Announces Promotion of Bryan Kim, D.M.D.
to Vice President of Asian Operations
|
| Blue
Bell, PA – July 1, 2007 – |
|
VGX Pharmaceuticals today announced the promotion
of Bryan Byong Jin Kim, D.M.D. to Vice President of Asian Operations.
Dr. Kim has been serving as the Senior Director of Corporate Development.
Since joining VGX in 2005, Dr. Kim has played an important role in various
corporate development operations including the acquisition of VGX International,
Inc. as well as the day-to-day management of this publicly-traded biopharmaceutical
company in Korea. VGX International was added to a KOSPI 200 index in
June, 2007. As VP of Asian Operations, Dr. Kim will oversee and coordinate
VGX’s strategic activities in Asia.
“Bryan has provided an invaluable service to our company,”
said Dr. J. Joseph Kim, CEO and President. “As a member of our executive
management team, he will continue to play an important role in our overall
strategy to become a dynamic global biopharmaceutical company,”
Dr. Bryan Kim has had extensive experience in building successful organizations
throughout his career. Prior to joining VGX, Dr. Kim was a successful
private clinician and a Clinical Assistant Professor at the University
of Pennsylvania, School of Dental Medicine, where he developed innovative
clinical programs and directed important research projects granted by
NIDH in microbiology and immunology.
Dr. Kim holds a Bachelor of Arts degree in Economics and a Bachelor of
Science degree in Biological Science, both from University of California
at Irvine and a Doctor of Dental Medicine degree from the University of
Pennsylvania.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecules
and biologics product candidates for the treatment of infectious diseases,
cancer and inflammatory diseases. The Company's clinical development programs
include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection,
both of which are currently in Phase II clinical trials. In addition, VGX
is planning to initiate Phase I clinical studies for VGX-1027, its lead
compound for inflammatory diseases. VGX's research pipelines include new
generation of DNA vaccines and therapeutics as well as CELLECTRA™,
a proprietary DNA delivery device. The product candidates and technology
programs are protected by the Company's extensive global intellectual property
portfolio. More information about VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
